Role of CD8+ T cells and lymphoid dendritic cells in protection from ocular herpes simplex virus 1 challenge in immunized mice

Journal of Virology

Volumn 88, Issue 14, 2014, Pages 8016-8027

  Matundan, Harry ^a   Mott, Kevin R ^a   Ghiasi, Homayon ^a  

^a Ophthalmology Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8ALPHA ANTIGEN; CD8BETA ANTIGEN; DNA; FMS LIKE TYROSINE KINASE 3 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES SIMPLEX VACCINE; LYMPHOCYTE ANTIGEN; NEUTRALIZING ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORNEA; DRUG EFFICACY; FEMALE; GENE DOSAGE; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; LATENT VIRUS INFECTION; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; TISSUE SPECIFICITY; TRIGEMINUS GANGLION; VACCINATION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION; WILD TYPE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CORNEA; DENDRITIC CELLS; HERPESVIRUS 1, HUMAN; HERPESVIRUS VACCINES; KERATITIS, HERPETIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTE SUBSETS; TRIGEMINAL GANGLION; VACCINES, ATTENUATED;

EID: 84904643987     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00913-14     Document Type: Article

References (89)

1. Jordan MC, Jordan GW, Stevens JG, Miller G. 1984. Latent herpesviruses of humans. Ann. Intern. Med. 100:866-880. http://dx.doi.org/10.7326/0003-4819-100-6-866.
2. Whitley RJ, Kimberlin DW, Roizman B. 1998. Herpes simplex viruses. Clin. Infect. Dis. 26:541-553. http://dx.doi.org/10.1086/514600.
3. Dawson CR. 1984. Ocular herpes simplex virus infections. Clin. Dermatol. 2:56-66. http://dx.doi.org/10.1016/0738-081X(84)90066-X.
4. Barron BA, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB, Wilhelmus KR, Kaufman HE, Sugar J, Hyndiuk RA, Laibson PR, Stulting RD, Asbell PA, for the Herpetic Eye Disease Study Group. 1994. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology 101:1871-1882.
5. Ghiasi H, Kaiwar R, Nesburn AB, Slanina S, Wechsler SL. 1994. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice. J. Virol. 68:2118-2126.
6. Lausch RN, Monteiro C, Kleinschrodt WR, Oakes JE. 1987. Superiority of antibody versus delayed hypersensitivity in clearance of HSV-1 from eye. Invest. Ophthalmol. Vis. Sci. 28:565-570.
7. Bonina L, Nash AA, Arena A, Leung KN, Wildy P. 1984. T cellmacrophage interaction in arginase-mediated resistance to herpes simplex virus. Virus Res. 1:501-505. http://dx.doi.org/10.1016/0168-1702(84) 90007-8.
8. Kunder SC, Wu L, Morahan PS. 1993. Role of NK cells in immunomodulator-mediated resistance to herpesvirus infection. Antiviral Res. 21:103-118. http://dx.doi.org/10.1016/0166-3542(93)90047-M.
9. Ghiasi H, Roopenian DC, Slanina S, Cai S, Nesburn AB, Wechsler SL. 1997. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Immunology 91:430-435. http://dx.doi.org/10.1046/j.1365-2567.1997.00261.x.
10. Ghiasi H, Cai S, Nesburn AB, Wechsler SL. 1997. MHC-II but not MHC-I responses are required for vaccine-induced protection against ocular challenge with HSV-1. Curr. Eye Res. 16:1152-1158. http://dx.doi.org /10.1076/ceyr.16.11.1152.5104.
11. Nash AA, Field HJ, Quartey-Papafio R. 1980. Cell-mediated immunity in herpes simplex virus-infected mice: induction, characterization and antiviral effects of delayed type hypersensitivity. J. Gen. Virol. 48:351-357. http://dx.doi.org/10.1099/0022-1317-48-2-351.
12. Kohl S, Loo LS, Drath DB, Cox P. 1989. Interleukin-2 protects neonatal mice from lethal herpes simplex virus infection: a macrophage-mediated, gamma interferon-induced mechanism. J. Infect. Dis. 159:239-247. http: //dx.doi.org/10.1093/infdis/159.2.239.
13. Kohl S. 1992. The role of antibody in herpes simplex virus infection in humans. Curr. Top. Microbiol. Immunol. 179:75-88.
14. Ghiasi H, Bahri S, Nesburn AB, Wechsler SL. 1995. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins. Invest. Ophthalmol. Vis. Sci. 36:1352-1360.
15. Ghiasi H, Wechsler SL, Kaiwar R, Nesburn AB, Hofman FM. 1995. Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1. J. Virol. 69:334-340.
16. Ghiasi H, Cai S, Perng GC, Nesburn AB, Wechsler SL. 2000. Both CD4+ and CD8+ T cells are involved in protection against HSV-1 induced corneal scarring. Br. J. Ophthalmol. 84:408-412. http://dx.doi.org /10.1136/bjo.84.4.408.
17. Erlich KS, Wofsy D, Dix RD, Mills J. 1989. Effects of selective depletion of L3T4+ T-lymphocytes on herpes simplex virus encephalitis. Clin. Immunol. Immunopathol. 52:190-201. http://dx.doi.org /10.1016/0090-1229(89)90171-2.
18. Dix RD. 1987. Prospects for a vaccine against herpes simplex virus types 1 and 2. Prog. Med. Virol. 34:89-128.
19. Oakes JE, Rector JT, Lausch RN. 1984. Lyt-1+ T cells participate in recovery from ocular herpes simplex virus type 1 infection. Invest. Ophthalmol. Vis. Sci. 25:188-194.
20. Nagafuchi S, Hayashida I, Higa K, Wada T, Mori R. 1982. Role of Lyt-1 positive immune T cells in recovery from herpes simplex virus infection in mice. Microbiol. Immunol. 26:359-362. http://dx.doi.org/10.1111/j.1348-0421.1982.tb00186.x.
21. Sethi KK, Omata Y, Schneweis KE. 1983. Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virusspecific and H-2-restricted cytotoxic T lymphocytes. J. Gen. Virol. 64: 443-447. http://dx.doi.org/10.1099/0022-1317-64-2-443.
22. Hendricks RL, Tumpey TM. 1990. Contribution of virus and immune factors to herpes simplex virus type I-induced corneal pathology. Invest. Ophthalmol. Vis. Sci. 31:1929-1939.
23. Staats HF, Oakes JE, Lausch RN. 1991. Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells. J. Virol. 65:6008-6014.
24. Manickan E, Rouse BT. 1995. Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse-models. J. Virol. 69:8178-8179.
25. Manickan E, Francotte M, Kuklin N, Dewerchin M, Molitor C, Gheysen D, Slaoui M, Rouse BT. 1995. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. J. Virol. 69:4711-4716.
26. Newell CK, Martin S, Sendele D, Mercadal CM, Rouse BT. 1989. Herpes simplex virus-induced stromal keratitis: role of T-lymphocyte subsets in immunopathology. J. Virol. 63:769-775.
27. Nash AA, Jayasuriya A, Phelan J, Cobbold SP, Waldmann H, Prospero T. 1987. Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. J. Gen. Virol. 68:825-833. http://dx.doi.org/10.1099/0022-1317-68-3-825.
28. Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL. 2000. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J. Exp. Med. 191:1459-1466. http://dx.doi.org /10.1084/jem.191.9.1459.
29. Bellone M, Iezzi G, Rovere P, Galati G, Ronchetti A, Protti MP, Davoust J, Rugarli C, Manfredi AA. 1997. Processing of engulfed apoptotic bodies yields T cell epitopes. J. Immunol. 159:5391-5399.
30. Albert ML, Sauter B, Bhardwaj N. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89. http://dx.doi.org/10.1038/32183.
31. Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C, Bellone M. 1999. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J. Immunol. 163:130-136.
32. Banchereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature 392:245-252. http://dx.doi.org/10.1038/32588.
33. Piccioli D, Sbrana S, Melandri E, Valiante NM. 2002. Contactdependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195:335-341. http://dx.doi.org/10.1084/jem.20010934.
34. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. 2002. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195:343-351. http://dx.doi.org/10.1084/jem.20011149.
35. Mott KR, Ghiasi H. 2008. Role of dendritic cells in enhancement of herpes simplex virus type 1 latency and reactivation in vaccinated mice. Clin. Vaccine Immunol. 15:1859-1867. http://dx.doi.org/10.1128/CVI.00318-08.
36. Vremec D, Zorbas M, Scollay R, Saunders DJ, Ardavin CF, Wu L, Shortman K. 1992. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J. Exp. Med. 176:47-58. http://dx.doi.org/10.1084/jem.176.1.47.
37. Anjuere F, Martin P, Ferrero I, Fraga ML, del Hoyo GM, Wright N, Ardavin C. 1999. Definition of dendritic cell subpopulations present in the spleen, Peyer's patches, lymph nodes, and skin of the mouse. Blood 93:590-598.
38. Becker Y. 2003. Milestones in the research on skin epidermal Langerhans/dendritic cells (LCs/DCs) from the discovery of Paul Langerhans 1868-1989. Virus Genes 26:131-134. http://dx.doi.org/10.1023/A:1023479212095.
39. + dendritic cells are involved in enhancing HSV-1 latency. J. Virol. 82:9870-9879. http://dx.doi.org/10.1128/JVI.00566-08.
40. Mott KR, Allen SJ, Zandian M, Konda B, Sharifi BG, Jones C, Wechsler SL, Town T, Ghiasi H. 2014. CD8a dendritic cells drive establishment of HSV-1 latency. PLoS One 9:e93444. http://dx.doi.org/10.1371/journal.pone.0093444.
41. + dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J. Exp. Med. 195: 1233-1245. http://dx.doi.org/10.1084/jem.20011930.
42. Grabbe S, Kampgen E, Schuler G. 2000. Dendritic cells: multi-lineal and multi-functional. Immunol. Today 21:431-433. http://dx.doi.org /10.1016/S0167-5699(00)01694-7.
43. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. 2000. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 164:2978-2986. http://dx.doi.org/10.4049/jimmunol.164.6.2978.
44. Zamoyska R. 1994. The CD8 coreceptor revisited: one chain good, two chains better. Immunity 1:243-246. http://dx.doi.org/10.1016/1074-7613(94)90075-2.
45. Devine L, Kieffer LJ, Aitken V, Kavathas PB. 2000. Human CD8 beta, but not mouse CD8 beta, can be expressed in the absence of CD8 alpha as a beta beta homodimer. J. Immunol. 164:833-838. http://dx.doi.org/10.4049/jimmunol.164.2.833.
46. Gorman SD, Sun YH, Zamoyska R, Parnes JR. 1988. Molecular linkage of the Ly-3 and Ly-2 genes. Requirement of Ly-2 for Ly-3 surface expression. J. Immunol. 140:3646-3653.
47. Perng GC, Dunkel EC, Geary PA, Slanina SM, Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL. 1994. The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J. Virol. 68:8045-8055.
48. Thompson RL, Cook ML, Devi-Rao GB, Wagner EK, Stevens JG. 1986. Functional and molecular analyses of the avirulent wild-type herpes simplex virus type 1 strain KOS. J. Virol. 58:203-211.
49. Thompson RL, Devi-Rao GV, Stevens JG, Wagner EK. 1985. Rescue of a herpes simplex virus type 1 neurovirulence function with a cloned DNA fragment. J. Virol. 55:504-508.
50. Dix RD, McKendall RR, Baringer JR. 1983. Comparative neurovirulence of herpes simplex virus type 1 strains after peripheral or intracerebral inoculation of BALB/c mice. Infect. Immun. 40:103-112.
51. Stroop WG, Banks MC. 1992. The weakly virulent herpes simplex virus type 1 strain KOS-63 establishes peripheral and central nervous system latency following intranasal infection of rabbits, but poorly reactivates in vivo. J. Neuropathol. Exp. Neurol. 51:550-559. http://dx.doi.org/10.1097 /00005072-199209000-00010.
52. Mizota A, Dix RD, Hamasaki DI. 1993. Bilateral electroretinographic changes induced by unilateral intra-visual cortex inoculation of herpes simplex virus type 1 in BALB/c mice. Doc. Ophthalmol. 84:213-230. http: //dx.doi.org/10.1007/BF01203654.
53. Crooks ME, Littman DR. 1994. Disruption of T lymphocyte positive and negative selection in mice lacking the CD8 beta chain. Immunity 1:277-285. http://dx.doi.org/10.1016/1074-7613(94)90079-5.
54. Mott K, Brick DJ, van Rooijen N, Ghiasi H. 2007. Macrophages are important determinants of acute ocular HSV-1 infection in immunized mice. Invest. Ophthalmol. Vis. Sci. 48:5605-5615. http://dx.doi.org/10.1167/iovs.07-0894.
55. Osorio Y, Cohen J, Ghiasi H. 2004. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines. Invest. Ophthalmol. Vis. Sci. 45:506-514. http://dx.doi.org/10.1167/iovs.03-0828.
56. Ghiasi H, Cai S, Slanina SM, Perng GC, Nesburn AB, Wechsler SL. 1999. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. J. Infect. Dis. 179:1086-1093. http: //dx.doi.org/10.1086/314736.
57. Holderried TA, Lang PA, Kim HJ, Cantor H. 2013. Genetic disruption of CD8+ Treg activity enhances the immune response to viral infection. Proc. Natl. Acad. Sci. U. S. A. 110:21089-21094. http://dx.doi.org/10.1073 /pnas.1320999110.
58. Allen SJ, Mott KR, Ljubimov AV, Ghiasi H. 2010. Exacerbation of corneal scarring in HSV-1 gK-immunized mice correlates with elevation of CD8+ CD25+ T cells in corneas of ocularly infected mice. Virology 399:11-22. http://dx.doi.org/10.1016/j.virol.2009.12.011.
59. Allen SJ, Mott KR, Zandian M, Ghiasi H. 2010. Immunization with different viral antigens alters the pattern of T cell exhaustion and latency in HSV-1 infected mice. J. Virol. 84:12315-12324. http://dx.doi.org/10.1128 /JVI.01600-10.
60. Allen SJ, Hamrah P, Gate DM, Mott KR, Mantopoulos D, Zheng L, Town T, Jones C, von Andrian UH, Freeman GJ, Sharpe AH, Benmohamed L, Ahmed R, Wechsler SL, Ghiasi H. 2011. The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus type 1. J. Virol. 85:4184-4197. http: //dx.doi.org/10.1128/JVI.02290-10.
61. McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, Maliszewski CR, Lynch DH, Smith J, Pulendran B, Roux ER, Teepe M, Lyman SD, Peschon JJ. 2000. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95:3489-3497.
62. Daro E, Pulendran B, Brasel K, Teepe M, Pettit D, Lynch DH, Vremec D, Robb L, Shortman K, McKenna HJ, Maliszewski CR, Maraskovsky E. 2000. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J. Immunol. 165:49-58. http://dx.doi.org/10.4049/jimmunol.165.1.49.
63. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maliszewski CR. 1999. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. U. S. A. 96:1036-1041. http://dx.doi.org/10.1073/pnas.96.3.1036.
64. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953-1962. http://dx.doi.org /10.1084/jem.184.5.1953.
65. Shurin MR, Pandharipande PP, Zorina TD, Haluszczak C, Subbotin VM, Hunter O, Brumfield A, Storkus WJ, Maraskovsky E, Lotze MT. 1997. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell. Immunol. 179:174-184. http://dx.doi.org/10.1006 /cimm.1997.1152.
66. Pulendran B, Lingappa J, Kennedy MK, Smith J, Teepe M, Rudensky A, Maliszewski CR, Maraskovsky E. 1997. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J. Immunol. 159:2222-2231.
67. Mott KR, Allen SJ, Zandian M, Akbari O, Hamrah P, Maazi H, Wechsler SL, Sharpe AH, Freeman GJ, Ghiasi H. 2014. Inclusion of CD80 in HSV targets the recombinant virus to PD-L1 on DCs and allows productive infection and robust immune responses. PLoS One 9:e87617. http://dx.doi.org/10.1371/journal.pone.0087617.
68. Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J, Caron D, Lebsack ME, McKenna HJ. 2000. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96:878-884.
69. Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C, Caron D, Maliszewski C, Davoust J, Fay J, Palucka K. 2000. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165:566-572. http://dx.doi.org/10.4049/jimmunol.165.1.566.
70. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, Fletcher FA, Maraskovsky E, Farrah T, Foxworthe D, Williams DE, Beckmann MP. 1993. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75: 1157-1167. http://dx.doi.org/10.1016/0092-8674(93)90325-K.
71. Sitnicka E, Bryder D, Theilgaard-Monch K, Buza-Vidas N, Adolfsson J, Jacobsen SE. 2002. Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool. Immunity 17:463-472. http://dx.doi.org/10.1016/S1074-7613(02)00419-3.
72. Lyman SD, Jacobsen SE. 1998. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 91: 1101-1134.
73. Shurin MR, Esche C, Lotze MT. 1998. FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev. 9:37-48. http://dx.doi.org/10.1016/S1359-6101(97)00035-X.
74. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, O'Garra A, Liu YJ. 2002. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 195:953-958. http://dx.doi.org/10.1084/jem.20020045.
75. Mott KR, Underhill D, Wechsler SL, Town T, Ghiasi H. 2009. A role for the JAK-STAT1 pathway in blocking replication of HSV-1 in dendritic cells and macrophages. Virol. J. 6:56. http://dx.doi.org/10.1186/1743-422X-6-56.
76. Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Cox WI, Steinman RM, Bhardwaj N. 1999. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163:6762-6768.
77. Granelli-Piperno A, Delgado E, Finkel V, Paxton W, Steinman RM. 1998. Immature dendritic cells selectively replicate macrophagetropic (Mtropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M-and T-tropic virus to T cells. J. Virol. 72:2733-2737.
78. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100: 587-597. http://dx.doi.org/10.1016/S0092-8674(00)80694-7.
79. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS. 2000. Human skin Langerhans cells are targets of dengue virus infection. Nat. Med. 6:816-820. http://dx.doi.org/10.1038/77553.
80. Mott KR, Allen SJ, Zandian M, Ghiasi H. 26 March 2014. Coregulatory interactions between CD8+ DCs, LAT, and PD-1 contribute to higher HSV-1 latency. J. Virol. http://dx.doi.org/10.1128/JVI.00590-14.
81. Kabashima K, Banks TA, Ansel KM, Lu TT, Ware CF, Cyster JG. 2005. Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 22:439-450. http://dx.doi.org/10.1016/j.immuni.2005.02.007.
82. De Trez C, Schneider K, Potter K, Droin N, Fulton J, Norris PS, Ha SW, Fu YX, Murphy T, Murphy KM, Pfeffer K, Benedict CA, Ware CF. 2008. The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J. Immunol. 180:238-248. http://dx.doi.org/10.4049/jimmunol.180.1.238.
83. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67:227-264. http: //dx.doi.org/10.1146/annurev.biochem.67.1.227.
84. Choubey D, Moudgil KD. 2011. Interferons in autoimmune and inflammatory diseases: regulation and roles. J. Interferon Cytokine Res. 31:857-865. http://dx.doi.org/10.1089/jir.2011.0101.
85. Moudgil KD, Choubey D. 2011. Cytokines in autoimmunity: role in induction, regulation, and treatment. J. Interferon Cytokine Res. 31:695-703. http://dx.doi.org/10.1089/jir.2011.0065.
86. Hall JC, Rosen A. 2010. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat. Rev. Rheumatol. 6:40-49. http://dx.doi.org/10.1038/nrrheum.2009.237.
87. Robbins SH, Walzer T, Dembele D, Thibault C, Defays A, Bessou G, Xu H, Vivier E, Sellars M, Pierre P, Sharp FR, Chan S, Kastner P, Dalod M. 2008. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol. 9:R17. http://dx.doi.org/10.1186/gb-2008-9-1-r17.
88. Shortman K, Lahoud MH, Caminschi I. 2009. Improving vaccines by targeting antigens to dendritic cells. Exp. Mol. Med. 41:61-66. http://dx.doi.org/10.3858/emm.2009.41.2.008.
89. Lauterbach H, Bathke B, Gilles S, Traidl-Hoffmann C, Luber CA, Fejer G, Freudenberg MA, Davey GM, Vremec D, Kallies A, Wu L, Shortman K, Chaplin P, Suter M, O'Keeffe M, Hochrein H. 2010. Mouse CD8alpha+DCs and human BDCA3+DCs are major producers of IFNlambda in response to poly IC. J. Exp. Med. 207:2703-2717. http://dx.doi.org/10.1084/jem.20092720.